Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which blood thinner is safer for clots? small study aims to find out

NCT ID NCT02559856

Disease control Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two common blood thinners, rivaroxaban and apixaban, in 72 adults with newly diagnosed blood clots in the legs or lungs. The main goal was to see if a larger trial is possible by checking how many patients could join and complete follow-ups. Researchers also tracked bleeding events and clot recurrences to assess safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

72 people

The number who actually took part.

Started

May 2016

Finished

Feb 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed newly diagnosed acute VTE (proximal lower extremity deep vein thrombosis and segmental or greater pulmonary embolism) * Age ≥ 18 years old * Written informed consent Exclusion Criteria: * Any contraindication for anticoagulation such as active bleeding * Clinically significant liver disease or alanine aminotransferase (ALT) levels ≥ 3 times the upper limit of normal range * Creatinine clearance \< 30 ml/min calculated with the Cockcroft-Gault formula (29) * Known allergies to either apixaban or rivaroxaban * Pregnancy * Use of contraindicated medications with apixaban or rivaroxaban * Active malignancy in the last 6 months (excluding localized skin malignancy) * No private insurance coverage for the study drug or not willing to pay for study drug

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Venous thromboembolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Venous thromboembolism

Contacts and locations

Locations

  • Hamilton General Hospital

    Hamilton, Ontario, L8L 2X2, Canada

  • Hôtel-Dieu de Sherbrooke

    Sherbrooke, Quebec, J1G 2E8, Canada

  • The Ottawa Hospital - General Campus

    Ottawa, Ontario, K1H 8L6, Canada

  • University of Alberta

    Edmonton, Alberta, T6G 2G3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.